A recent post here flagged two areas — self-driving cars and package delivery by drone aircraft — where regulation is moving slower than technology. A recent Manhattan Institute report flags another one: precision medicine, in which drug treatments are tailored to the biomarkers or genes of individual patients. The FDA, the report says, "has been very slow to act," instead insisting on the old model of large clinical trials that "assume broad areas of biochemical uniformity among patients, where we now know that there is significant variation."
Regulation Lags Technology, Again
by Editor | Related Topics: Health Care, Regulation receive the latest by email: subscribe to the free futureofcapitalism.com mailing list